Advertisement

Reactions Weekly

, Volume 1735, Issue 1, pp 197–197 | Cite as

Nivolumab

Hyperprogression of non small cell lung cancer and associated complications: 5 case reports
Case report
  • 18 Downloads
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

A retrospective review between January 2016 and January 2018 described 5 patients, aged 53−83 years, who developed hyperprogression of non small cell lung cancer, leading to various complications in four patients (cases 1, 2, 3 and 5), during treatment with nivolumab for non small cell lung cancer [routes, dosages and durations of treatment to reactions onset not stated].

Case 1: A 69-year-old man underwent concurrent chemoradiotherapy for stage IIIB squamous cell carcinoma from March−May 2015. The primary lung tumour recurred, and nivolumab was started as a second line therapy in May 2016. After nivolumab therapy, he began complaining dyspnoea. Oxygenation status and symptoms began to rapidly deteriorate. On a chest X-ray tumour progression was noted. After two cycles of...

Reference

  1. Kanazu M, et al. Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series. Thoracic Cancer 9: 1782-1787, No. 12, Dec 2018. Available from: URL: http://doi.org/10.1111/1759-7714.12894 - JapanCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Personalised recommendations